On November 14, Tianguangshi Biotech announced that its self-developed innovative biological preparation Beijiexin® Dual Indication was successfully included in the new medical insurance catalogue. In February of this year, Beijiexin® was approved to treat neuromyelitis optic disease with positive anti-water channel protein 4 antibodies. In June of the same year, it was also approved for use in adult patients with medium- to high-risk primary membranous nephropathy, making it the first drug approved for pMN in the world.

Zhitongcaijing · 2d ago
On November 14, Tianguangshi Biotech announced that its self-developed innovative biological preparation Beijiexin® Dual Indication was successfully included in the new medical insurance catalogue. In February of this year, Beijiexin® was approved to treat neuromyelitis optic disease with positive anti-water channel protein 4 antibodies. In June of the same year, it was also approved for use in adult patients with medium- to high-risk primary membranous nephropathy, making it the first drug approved for pMN in the world.